Given the profound anti-tumor effects of genetic EZH2 knockdown in combination with therapy-induced senescence in PDAC, we next tested whether small molecule EZH2 inhibitors that are in clinical development could achieve similar responses. This evidence concerns the gene EZH2 and neoplasm.